Novel Immune Response Discovered That May Boost Cancer Defense

Researchers find CD4+ T cells can attack cancer cells that evade CD8+ T cells

Mar. 25, 2026 at 1:54am

Got story updates? Submit your updates here. ›

In a groundbreaking study, researchers at Baylor College of Medicine and the University of Michigan Rogel Cancer Center have discovered a novel way the immune system, specifically T-cells, can attack their target cells. The study challenges long-held assumptions in immunology and has direct implications for cancer immunology and bone marrow transplantation.

Why it matters

This research reshapes our understanding of how the immune system works and could lead to new strategies to make immunotherapies more effective, especially against tumors that evade traditional CD8+ T cell responses. It also suggests a role for MHC class I in regulating tissue sensitivity to CD4+ T cell-mediated attacks, which could have implications beyond cancer and transplant immunology.

The details

The researchers found that when cancer cells lose MHC I expression - a common strategy to evade CD8+ 'killer' T cell attack - they become more vulnerable to attack from CD4+ 'helper' T cells. Without MHC I expression, cancer cells are more sensitive to ferroptosis, a type of cell death driven by iron and oxidative stress, when triggered by CD4+ T cells. This induction of ferroptosis was observed not only in cancer, but also in models of graft-versus-host disease, a complication of bone marrow transplants.

  • The study was published in Nature Immunology on March 25, 2026.

The players

Dr. Pavan Reddy

Director of the Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine and lead author of the study.

Dr. Arul Chinnaiyan

S.P. Hicks Endowed Professor of Pathology at the University of Michigan Rogel Cancer Center and co-author of the study.

Dr. Marcin Cieslik

Assistant professor of pathology at the University of Michigan Rogel Cancer Center and co-author of the study.

Got photos? Submit your photos here. ›

What they’re saying

“Our work, if further validated, will have implications for T cell-mediated immune responses beyond cancer and transplant immunology. This may allow for the development of novel strategies that target MHC class I and CD4+ T cells to leverage the beneficial side of immunity or mitigate unwanted immune responses.”

— Dr. Pavan Reddy, Director, Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine

What’s next

Researchers plan to further validate these findings and explore their potential applications in developing new cancer immunotherapy strategies.

The takeaway

This groundbreaking discovery challenges long-held assumptions in immunology and could lead to more effective cancer treatments by harnessing the power of CD4+ 'helper' T cells to attack cancer cells that evade traditional CD8+ 'killer' T cell responses.